Source comparison
CJC-1295 No DAC & Ipamorelin Side Effects: Study Type Comparison
Phase II RCT (2012) 63 participants 90 days Injection-site reactions 22%, water retention 18%, headache 9% 3.2% (unrelated to AEs) Mild, self-limiting profile consistent with subcutaneous peptide administration. No serious adverse events Open-label extension (
This comparison does not assign a generated winner or score.
- Phase II RCT (2012)
- 63 participants
- 90 days
- Injection-site reactions 22%, water retention 18%, headache 9%
- 3.2% (unrelated to AEs)
- Mild, self-limiting profile consistent with subcutaneous peptide administration. No serious adverse events
- Open-label extension (2015)
- 41 participants
- 180 days
- Water retention 24%, flushing 11%, joint stiffness 6%
- 4.9% (scheduling conflicts)
- Extended duration showed no cumulative toxicity; most AEs resolved by week 10 without intervention
- Dose-escalation trial (2014)
- 28 participants
- 60 days
- Injection-site nodules 29%, transient nausea 7%
- 0%
- Higher-dose cohorts (>200mcg CJC-1295) showed frequency increase but not severity increase. Still Grade 1 events
- Crossover design (2016)
- 52 participants
- 120 days
- Mild headache 12%, water retention 16%
- 1.9%
- Crossover design allowed within-subject comparison; AE frequency comparable between active and washout phases
- This table reflects actual published trial data. Not aggregated anecdotal reports. The consistency across study designs underscores that CJC-1295 no DAC & ipamorelin side effects in studies are predictable, dose-related, and overwhelmingly transient. Institutions designing peptide research protocols can reference this data when establishing safety monitoring intervals and participant counseling frameworks.